Global Cytomegalovirus Infection Treatment Market Research Report 2017

Bharat Book Bureau Provides the Trending Market Research Report on Global Cytomegalovirus Infection Treatment Market Opportunity Analysis And Industry Forecast 2017 – 2023 under Life Science category. The report provides information on industry overview, market size, latest developments, industry trends, Key players, global presence, and their future prospects.

Global Cytomegalovirus Infection Treatment Market
 
Cytomegalovirus (CMV) infection is the common herpes virus infection having different symptoms which occurs in all ages of people around the world. Cytomegalovirus (CMV) infection is a communicable and easily prone through the body fluids like urine, saliva, blood, breast milk and semen. The infection may spread fast from urine or saliva from people who are infected with CMV having virus in their bodily fluids. The disease can transmit from pregnant to baby during delivery. Organ transplant and Blood transfusion are the other way for the transmission of the disease.

Request a free sample copy of Cytomegalovirus Infection Treatment Market Report @
https://www.bharatbook.com/request-sample/992173

Cytomegalovirus infection treatment market is mainly propelling by the rise in the prevalence of CMV infections, growing awareness about herpes disease, pipeline drugs which are promising by key market players for the treatment of CMV infection. Moreover, rise in the support of government, and development of healthcare infrastructure are anticipated to fuel the growth of CMV infection treatment market. However, recent expiries of patented drugs, generic drugs that are available for the treatment like Ganciclovir & Foscarnet are anticipated to hamper the market growth of cytomegalovirus infection treatment.
 
The global cytomegalovirus infection market is classified on the basis of drug class, infection, distribution channel, and geography.
 
Based on drug class, the global cytomegalovirus infection market is segmented into the following:
- Antiviral drugs
- Foscarnet
- Cytovene
- Vistide
- Others
 
Based on infection, the global cytomegalovirus infection market is segmented into the following
- Retinitis
- Pneumonia
- Gastroenteritis
- Others (Mouth Ulcers, Pharyngitis, etc.)
 
Based on distribution channel, the global cytomegalovirus infection market is segmented into the following:
- Hospital Pharmacies
- Retail Pharmacies
- Others
 
Global cytomegalovirus infection treatment market is anticipated to show effective growth rate in foresee period. Players in the market are heavily investing in R&D for the development of novel therapies and drugs to treat cytomegalovirus infection. Moreover, regulatory bodies of the healthcare sector are having more attention on novel drugs by giving faster approvals and special status for the drugs. For instance, Merck & Co. Inc., developed Letermovir, antiviral drug for the treatment of CMV infection. The drug has received fast track status by the U.S. FDA and the orphan drug status by European Medicines Agency.
 
On the basis of Geographical regions, CMV infection treatment market is classified as into five key regions as Europe, Asia- Pacific, North America, Middle East & Africa and Latin America. North America & Europe were anticipated to contribute major share in the cytomegalovirus infection treatment market due to the high prevalence rate of cytomegalovirus infection. As per Centre for Disease Control and Prevention (CDC), approximately, 80,000 cases of CMV infections were diagnosed in U.S. and Europe. Increased prevalence of cytomegalovirus (CMV) infection in the developing countries and in the areas of lower economic status. Asia-Pacific is anticipated to grow rapidly owing to the large patient pool, and rise in prevalence of many infectious diseases as well as rise in the awareness on cytomegalovirus infections.
 
Some of the players in cytomegalovirus infection market are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.), AiCuris Anti-infective Cures GmbH (Germany) Vical, Inc. (U.S.), Chimerix, Inc. (U.S.) and ViroPharma (U.S.), to name a few
 
In Feb 2017, Merck & Co., Inc. started pivotal Phase 3 clinical study of letermovir, an antiviral investigational drug for treating clinically significant cytomegalovirus Infection

Browse our full report with Table of Contents :  
https://www.bharatbook.com/healthcare-market-research-reports-992173/cytomegalovirus-infection-treatment-global.html

About Bharat Book Bureau: 
Bharat Book Bureau is the leading market research information provider for market research reports, company profiles, industry study, country reports, business reports, newsletters and online databases. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology. 

Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email: poonam@bharatbook.com
Website: www.bharatbook.com

Follow us on : Twitter, Facebook, LinkedIn, Google Plus

About This Author

licia Joined: August 3rd, 2017